UTRxM1-18 / UTR Therap - LARVOL DELTA

UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA Therapeutic (GlobeNewswire) - "UTRxM1-18 produced dose-dependent tumor regression, 100% complete pathological responses at the highest tested dose, and significant inhibition of liver, lung, and brain metastases in preclinical pancreatic cancer models....UTR Therapeutics plans to initiate a Phase 1 trial of UTRxM1-18 in patients with advanced c-MYC–driven tumors pending regulatory approvals."

New P1 trial • Preclinical • Pancreatic Cancer

UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers (GlobeNewswire) - "UTR Therapeutics...is pleased to announce a new milestone, the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for UTRxM1-18, a novel therapeutic approach for targeting c-MYC driven cancers....UTRxM1-18 harnesses UTR’s proprietary Ultra-Targeted RNA platform to degrade disease-causing transcripts with ultra-high precision and specificity....Our first-in-human Phase 1 trial is slated for 2026, pending FDA approval."

IND • New P1 trial • Solid Tumor